The surgical application of point-of-care haemostasis and platelet function testing

British Journal of Surgery

Volumn 95, Issue 11, 2008, Pages 1317-1330

  Dickinson, K J ^a   Troxler, M ^a   Homer Vanniasinkam, S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DESMOPRESSIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIIA; HEPARIN; HYPERTENSIVE AGENT; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANALYZER; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOVASCULAR SURGERY; DISEASE PREDISPOSITION; HEART INFARCTION; HEMOSTASIS; LIVER SURGERY; MEDLINE; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; RISK; STROKE; SURGICAL TECHNIQUE; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SURGICAL PROCEDURES; HEMOSTASIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; POSTOPERATIVE HEMORRHAGE; THROMBELASTOGRAPHY; THROMBOEMBOLISM;

EID: 55549136735     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6359     Document Type: Review

References (113)

1. Stief TW, Fareed J. Point of care: diagnostics in hemostasis - the wrong direction? Clin Appl Thromb Haemost 2003; 9: 191-195.
2. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-744.
3. Born GVR. Aggregation of blood platelets by adenosine and its reversal. Nature 1962; 194: 927-929.
4. Lodge JPA. Hemostasis in liver resection surgery. Semin Hematol 2004; 41(Suppl 1): 70-75.
5. Belghiti J, Noun R, Zante E, Ballet T, Sauvanet A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg 1996; 224: 155-161.
6. Pringle JH. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 1908; 48: 541-549.
7. Thompson JF, Mullee MA, Bell PR, Campbell WB, Chant AD, Darke SG et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg 1996; 12: 86-90.
8. Byun Y, Singh VK, Yang VC. Low molecular weight protamine: a potential non-toxic heparin antagonist. Thromb Res 1999; 94: 53-61.
9. Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal aortic aneursysms. Ann Thorac Surg 2007; 83: S862-S864.
10. Conrad MF, Crawford RS, Davison JK, Cambria RP. Thoracoabdominal aneurysm repair: a 20-year perspective. Ann Thorac Surg 2007; 83: S856-S861.
11. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271-279.
12. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104: 94-107.
13. Despotis GJ, Joist JH, Goodnough LT. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997; 43: 1684-1696.
14. Hirsh J. Heparin. N Engl JMed 1991; 324: 1565-1574.
15. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008-1014.
16. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contributing to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62-67.
17. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 2145-2152.
18. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective α-granule release. Blood 1980; 56: 824-834.
19. Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH Jr. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93: 2014-2018.
20. Aldea GS, Soltow LO, Chandler WL, Triggs CM, Vocelka CR, Crockett GI et al. Limitation of thrombin generation, platelet activation and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002; 123: 742-755.
21. Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. Effects of cardiac surgery on hemostasis. Transfus Med Rev 2006; 20: 230-241.
22. Hett DA, Walker D, Pilkington SN, Smith DC. Sonoclot analysis. Br J Anaesth 1995; 75: 771-776.
23. Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EE, Murday AJ et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995; 59: 664-667.
24. Poston R, Gu J, Manchio J, Lee A, Brown J, Gammie J et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005; 27: 584-591.
25. Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyser (PFA-100®) and modified thromboelastography (mTEG®) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676-683.
26. Tanaka KA, Szlam F, Kelly AB, Vega JD, Levy JH. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets 2004; 15: 325-332.
27. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49: 2145-2150.
28. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-641.
29. Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci 2002; 27: 83-92.
30. Geeraedts LM Jr, Demiral H, Schaap N, Kamphuisen PW, Pompe JC, Frolke JP. 'Blind' transfusion of blood products in exsanguinating trauma patients. Resuscitation 2007; 73: 382-388.
31. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-1082.
32. Shirota K, Watanabe T, Takagi Y, Ohara Y, Usui A, Yasuura K. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. Artif Organs 2000; 24: 49-56.
33. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9: 168-173.
34. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thromboelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgical patients. J Lab Clin Med 2005; 145: 309-315.
35. Slater NPG. The risk of infection transfer by blood transfusion. Curr Pract Surg 1993; 5: 122-126.
36. Parrot NR. Blood transfusion: should we avoid it in our cancer patients? Curr Pract Surg 1993; 5: 127-131.
37. Jensen LS, Anderson AJ, Christensen PM, Hokland P, Juhl CO, Madsen G et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513-516.
38. Zucker ML, Jobes C, Siegel M, Jobes D, LaDuca FM. Activated clotting time (ACT) testing: analysis of reproductibility. J Extra Corpor Technol 1999; 31: 130-134.
39. Despotis GJ, Levine V, Filos K, Santoro SA, Joist JH, Spitznagel E et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85: 1311-1323.
40. Despotis GJ, Levine V, Saleem R, Spitznagel E, Joist JH. Use of point-of-care identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 1999; 354: 106-110.
41. Ereth MH, Nuttall GA, Santrach PJ, Klindworth JT, Oliver WC Jr, Schaff HV. The relation between the platelet-activated clotting test (HemoSTATUS) and blood loss after cardiopulmonary bypass. Anesthesiology 1998; 88: 962-969.
42. Forestier F, Coiffic A, Mouton C, Ekouevi D, Chene G, Janvier G. Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth 2002; 89: 715-721.
43. Isgro F, Rehn E, Kiessling AH, Kretz KU, Kilian W, Saggau W. Platelet function test HemoSTATUS 2: tool or toy for optimised management of hemostasis? Perfusion 2002; 17: 27-31.
44. Shanberge JN, Murato M, Quattrociocchi-Longe T, van Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol 1987; 87: 210-217.
45. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by activated clotting time. Perfusion 2003; 18: 277-281.
46. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18: 269-276.
47. Pappalardo F, Franco A, Crescenzi G, de Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 2006; 21: 285-290.
48. Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837-841.
49. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008; 22: 47-52.
50. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46.
51. Welsby IJ, Jiao K, Ortel TL, Brudney CS, Roche AM, Bennett-Guerrero E et al. The kaolin-activated Thromboelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20: 531-535.
52. Shih RL, Cherng YG, Chao A, Chen JT, Tsai AL, Lin CC. Prediction of bleeding diathesis in patients undergoing cardiopulmonary bypass during cardiac surgery: viscoelastic measures versus routine coagulation testing. Acta Anaesthesiol Sin 1997; 35: 133-139.
53. Ostrowsky J, Foes J, Warchol M, Tsarovsky G, Blay J. Plateletworks platelet function test compared to the thromboelastograph for prediction of post-operative outcomes. J Extra Corpor Technol 2004; 36: 149-152.
54. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vale-Cantos F, Ergin MA. Thromboelastography guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-319.
55. Cherng YG, Chao A, Shih RL, Lin CS, Chan WH, Huang CH et al. Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin 1998; 36: 179-186.
56. McNicol PL, Liu G, Harley ID, McCall PR, Przybylowski GM, Bowkett J et al. Blood loss and transfusion requirements in liver transplantation: experience with the first 75 cases. Anaesth Intensive Care 1994; 22: 666-671.
57. Gillies BS. Thromboelastography and liver transplantation. Semin Thromb Hemost 1995; 21(Suppl 4): 45-49.
58. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BWJr et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-896.
59. Hendriks HG, Meijer K, de Wolf JT, Porte RJ, Klompmaker IG, Lip H et al. Effect of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002; 13: 309-313.
60. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gross A et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thromboelastography. J Thromb Haemost 2006; 5: 289-295.
61. Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thromboelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma 2007; 62: 1352-1359.
62. Vig S, Chitolie A, Bevan DH, Halliday A, Dormandy J. Thromboelastography: a reliable test? Blood Coagul Fibrinolysis 2001; 12: 555-561.
63. Samama CM, Ozier Y. Near-patient testing of haemostasis in the operating theatre: an approach to appropriate use of blood in surgery. Vox Sang 2003; 84: 251-255.
64. von Kualla KN, Ostendorf P, von Kaulla E. The impedance machine: a new bedside coagulation recording device. J Med 1975; 6: 73-88.
65. Tuman KJ, Speiss BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic methods of coagulation after cardiopulmonary bypass. Anaesth Analg 1989; 69: 69-75.
66. Yamada T, Katori N, Tanaka KA, Takeda J. Impact of Sonoclot hemostasis analysis after cardiopulmonary bypass on postoperative hemorrhage in cardiac surgery. J Anesth 2007; 21: 148-152.
67. Faraday N, Guallar E, Sera VA, Bolton ED, Scharpf RB, Cartarius AM et al. Utility of whole blood hemostatometry using the Clot Signature Analyzer for assessment of hemostasus in cardiac surgery. Anesthesiology 2002; 96: 1115-1122.
68. Maquelin KN, Berckmans RJ, Nieuwland R, Schaap MC, ten Have K, Eijsman L et al. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 115: 1160-1165.
69. de Haan J, van Oeveren W. Platelets and soluble fibrin promote plasminogen actvation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin. Thromb Res 1998; 92: 171-179.
70. Greilich PE, Brouse C, Beckham J, Jessen ME, Martin EJ, Carr ME. Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Thromb Res 2002; 105: 523-529.
71. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2006; 113: e166-e286.
72. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lochowandt U et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothoracic Surg 2008; 34: 73-92.
73. Lennon MJ, Gibbs NM, Weightman WM, McGuire D, Michalopolous M. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18: 136-140.
74. von Beckerath N, Pogatsa Murray G, Wieczoek A, Sibbing D, Schomig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
75. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
76. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised controlled trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
77. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
78. Sonsken JR, Kong KL, Holder R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 1999; 82: 360-365.
79. Fiore LD, Brophy MT, Lopez A, Janson P, Deykin D. The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol 1990; 94: 292-296.
80. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336.
81. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
82. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
83. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, HackeWet al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28: 2200-2207.
84. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al, MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recurrent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
85. Swallow RA, Agarwala RA, Dawkins KD, Curzen NP. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006; 17: 385-392.
86. Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S. Quantifying the effect of anti-platelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105: 676-683.
87. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-666.
88. Hobson AR, Petley GW, Dawkins KD, Curzen N. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thromboelastography. Platelets 2007; 18: 497-505.
89. Cerutti E, Stratta C, Romagnoli R, Schellino MM, Skurzak S, Rizzetto M et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl 2004; 10: 289-294.
90. Mahla E, Lang T, Vicenzi MN, Werkgartner G, Maier R, Probst C et al. Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg 2001; 92: 572-577.
91. Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277-281.
92. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of anti-platelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002; 13: 493-497.
93. Hertfelder HJ, Bos M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost 2005; 31: 426-440.
94. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergio B, Grazia AM et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007; 121: 407-412.
95. Reny JL, Moerloose DE, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
96. Mueller T, Haltmayer M, Poeiz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovasc Surg 2003; 37: 117-123.
97. Anderson K, Hurlen M, Amesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003; 108: 37-42.
98. Wong S, Ward C, Appleberg M, Lewis DR. Point of care testing of aspirin resistance in patients with vascular disease. ANZ J Surg 2006; 76: 873-877.
99. Panniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007; 128: 143-149.
100. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005; 101: 71-76.
101. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005; 130: 759-767.
102. Kotzailias N, Elwischger K, Sycha T, Rinner W, Quehenberger P, Auff E et al. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J Stroke Cerebrovasc Dis 2007; 16: 199-202.
103. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory direction. J Thromb Haemost 2007; 5(Suppl 1): 230-237.
104. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
105. Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD et al. The Ultegra rapid platelet function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002; 143: 602-611.
106. Hochholzer W, Trenk D, Frundi D, Neumann FJ. Whole blood aggregometry for the evaluation of the anti-platelet effects of clopidogrel. Thromb Res 2007; 119: 285-291.
107. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moltierno DJ et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Circulation 2001; 103: 2572-2578.
108. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
109. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D et al. Monitoring platelet inhibition after clopidogrel with the Verfiy Now-P2Y12® rapid analyzer: the VERIfy Thrombosis risk ASsesssment (VERITAS) study. Thromb Res 2007; 119: 277-284.
110. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120: 631-635.
111. Harrison P, Segal H, Silver L, Syed A, Cutherbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119-124.
112. Christiaens L, Macchi L. Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact? Curr Vasc Pharmacol 2007; 5: 293-301.
113. Mahmud E, Ang L. Monitoring antiplatelet therapy during peripheral vascular and coronary interventions. Tech Vasc Interv Radiol 2006; 9: 56-63.